AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY TO DESCRIBE TREATMENT PATHWAYS AND OUTCOMES FOR CLASSICAL HODGKIN LYMPHOMA IN EAST ASIA: INTERIM RESULTS
Author(s): ,
Tae Min Kim
Affiliations:
Division of Hematology and Medical Oncology, Department of Internal Medicine,Seoul National University Hospital,Seoul,Korea, Republic Of
,
Yuqin Song
Affiliations:
Peking University Cancer Hospital,Beijing,China
,
Yok Lam Kwong
Affiliations:
Queen Mary Hospital,Hong Kong,Hong Kong;Hematology Division, Medical Oncology and Bone Marrow Transplantation,University of Hong Kong,Hong Kong,Hong Kong
,
Soon Thye Lim
Affiliations:
National Cancer Centre,Singapore,Singapore
,
Arif Abdillah
Affiliations:
Takeda Pharmaceuticals International AG,Singapore,Singapore
,
Maria Kudela
Affiliations:
Millennium Pharmaceuticals,Cambridge,United States
,
Mehul R. Dalal
Affiliations:
Millennium Pharmaceuticals,Cambridge ,United States
Su-Peng Yeh
Affiliations:
Division of Hematology and Oncology, Tissue Bank, Organ Preservation Bank, and Stem Cell Laboratory,China Medical University Hospital,Taichung,Taiwan, Province of China
(Abstract release date: 05/14/20) EHA Library. Min Kim T. 06/12/20; 293631; EP1142
Tae Min Kim
Tae Min Kim
Contributions
Abstract

Abstract: EP1142

Type: e-Poster

Background

Classical Hodgkin lymphoma (cHL) is the most common histological form of HL (~95% of cases). With recent therapeutic advances, more than 80% of all newly diagnosed patients under the age of 60 are likely to achieve cure. However, most studies performed to date have been undertaken in Europe or North America and information regarding patient outcomes in other regions is limited.

Aims
The B-CD30+ HOdgkin Lymphoma International Multi-Centre Retrospective Study of Treatment PractIces and OutComes (B-HOLISTIC) was designed to assess cHL treatment pathways, clinical outcomes and healthcare resource utilization in countries across Latin America, Africa, the Middle East and Asia-Pacific. Data from East Asia as of 14 December 2019 are presented here.

 

Methods
Retrospective data were collected for adult patients (≥18 years) newly diagnosed with stage IIB–IV cHL or relapsed/refractory cHL (RRHL) between 01 January 2010 and 31 December 2013. Data for each patient were collected until death or last follow-up in chart review, whichever occurred first. Patients with an initial diagnosis of cHL and subsequent progression to relapsed/refractory HL (RRHL) were included in both groups, provided that RRHL was diagnosed within the study period. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Secondary endpoints included overall survival (OS), best clinical response after completion of treatment, response duration and adverse events (AEs).

Results
A total of 156 patients were enrolled from five countries in East Asia (China n=88; Taiwan n=42; Singapore n=19; Hong Kong n=5; South Korea n=2). In the cHL cohort (n=147), the median age (range) at diagnosis was 31 (18–88) years and 92/147 (62.6%) were male. Distribution according to clinical stage II, III and IV disease was 35/147 (23.8%), 65/147 (44.2%), and 47/147 (32.0%). All patients with cHL received chemotherapy as frontline treatment: the combination of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) was initially used in 131/147 (89.1%) of cases. Consolidation radiotherapy was given in 18/147 (12.2%) of cases. Twenty patients with an initial diagnosis of cHL progressed to RRHL during the study period. In the RRHL cohort (n=29), the median age (range) at diagnosis was 34 (20–73) years and 18/29 (62.1%) were male. At RRHL diagnosis, intensive chemotherapy was used second line in 27/29 (93.1%) of patients and included a range of first salvage regimens: ifosfamide, carboplatin, etoposide (ICE), 4/27 (14.8%); cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), 4/27 (14.8%); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP), 3/27 (11.1%). Among the 29 patients with RRHL, 23 (79.3%) were eligible for haematopoietic stem cell transplantation (HSCT) and 11 (47.8%) underwent treatment. Estimated PFS rates for patients with RRHL at 1 and 3 years was 36.0% (95% CI 18.5–53.8) and 24.0% (95% CI 9.9–41.4). Further clinical outcomes are presented in Table 1. AEs were reported by 95/147 (64.6%) patients with cHL and by 26/29 (89.7%) patients with RRHL. Serious AEs (SAEs) were reported by 17/147 (11.6%) patients with cHL and by 7/29 (24.1%) patients with RRHL.

Conclusion
In line with other countries, ABVD was the most common treatment in East Asian patients with cHL. The 5-year PFS and OS in the cHL cohort are comparable with previous studies from Europe and the USA in Caucasian patients. For patients with RRHL, low rates of PFS and OS underscore the importance of novel treatments.

Session topic: 17. Hodgkin lymphoma - Clinical

Keyword(s): Ethnicity, Hodgkin's lymphoma, Progression, Survival

Abstract: EP1142

Type: e-Poster

Background

Classical Hodgkin lymphoma (cHL) is the most common histological form of HL (~95% of cases). With recent therapeutic advances, more than 80% of all newly diagnosed patients under the age of 60 are likely to achieve cure. However, most studies performed to date have been undertaken in Europe or North America and information regarding patient outcomes in other regions is limited.

Aims
The B-CD30+ HOdgkin Lymphoma International Multi-Centre Retrospective Study of Treatment PractIces and OutComes (B-HOLISTIC) was designed to assess cHL treatment pathways, clinical outcomes and healthcare resource utilization in countries across Latin America, Africa, the Middle East and Asia-Pacific. Data from East Asia as of 14 December 2019 are presented here.

 

Methods
Retrospective data were collected for adult patients (≥18 years) newly diagnosed with stage IIB–IV cHL or relapsed/refractory cHL (RRHL) between 01 January 2010 and 31 December 2013. Data for each patient were collected until death or last follow-up in chart review, whichever occurred first. Patients with an initial diagnosis of cHL and subsequent progression to relapsed/refractory HL (RRHL) were included in both groups, provided that RRHL was diagnosed within the study period. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Secondary endpoints included overall survival (OS), best clinical response after completion of treatment, response duration and adverse events (AEs).

Results
A total of 156 patients were enrolled from five countries in East Asia (China n=88; Taiwan n=42; Singapore n=19; Hong Kong n=5; South Korea n=2). In the cHL cohort (n=147), the median age (range) at diagnosis was 31 (18–88) years and 92/147 (62.6%) were male. Distribution according to clinical stage II, III and IV disease was 35/147 (23.8%), 65/147 (44.2%), and 47/147 (32.0%). All patients with cHL received chemotherapy as frontline treatment: the combination of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) was initially used in 131/147 (89.1%) of cases. Consolidation radiotherapy was given in 18/147 (12.2%) of cases. Twenty patients with an initial diagnosis of cHL progressed to RRHL during the study period. In the RRHL cohort (n=29), the median age (range) at diagnosis was 34 (20–73) years and 18/29 (62.1%) were male. At RRHL diagnosis, intensive chemotherapy was used second line in 27/29 (93.1%) of patients and included a range of first salvage regimens: ifosfamide, carboplatin, etoposide (ICE), 4/27 (14.8%); cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), 4/27 (14.8%); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP), 3/27 (11.1%). Among the 29 patients with RRHL, 23 (79.3%) were eligible for haematopoietic stem cell transplantation (HSCT) and 11 (47.8%) underwent treatment. Estimated PFS rates for patients with RRHL at 1 and 3 years was 36.0% (95% CI 18.5–53.8) and 24.0% (95% CI 9.9–41.4). Further clinical outcomes are presented in Table 1. AEs were reported by 95/147 (64.6%) patients with cHL and by 26/29 (89.7%) patients with RRHL. Serious AEs (SAEs) were reported by 17/147 (11.6%) patients with cHL and by 7/29 (24.1%) patients with RRHL.

Conclusion
In line with other countries, ABVD was the most common treatment in East Asian patients with cHL. The 5-year PFS and OS in the cHL cohort are comparable with previous studies from Europe and the USA in Caucasian patients. For patients with RRHL, low rates of PFS and OS underscore the importance of novel treatments.

Session topic: 17. Hodgkin lymphoma - Clinical

Keyword(s): Ethnicity, Hodgkin's lymphoma, Progression, Survival

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies